Critically ill children are susceptible to nosocomial infections, which contribute to adverse outcomes. Deficiencies in the innate immunity lectin pathway of complement activation are implicated in a child's vulnerability to infections in conditions such as cancer, but the role during critical illness remains unclear. We hypothesized that low on-admission levels of the pathway proteins are, in part, genetically determined and associated with susceptibility to infectious complications and adverse outcomes. Methods: We studied protein levels of mannose-binding lectin (MBL), H-ficolin and M-ficolin, three MBL-associatedserine proteases (MASPs) and MBL-associated protein (MAp44), and relation with functional genetic polymorphisms, in 130 healthy children and upon intensive care unit (ICU) admission in 700 critically ill children of a randomized study on glycemic control. results: Levels of MASP-1, MASP-2, MASP-3, and MAp-44 were lower and the levels of M-ficolin were higher in ICU patients on admission than those in matched healthy controls. Only a low on-admission MASP-3 level was independently associated with risk of new ICU infections and prolonged ICU stay, after correcting for other risk factors. On-admission MASP-3 varied with age, illness severity, and genetic variation. conclusion: Low on-admission MASP-3 levels in critically ill children were independently associated with subsequent acquisition of infection and prolonged ICU stay. The biological explanation needs further investigation.
c hildren are admitted to the intensive care unit (ICU) most often after major or life-threatening surgery, extensive trauma, or serious infection. Clinically diagnosed nosocomial infection is a substantial problem occurring in ~30% of these patients (1) . Systemic inflammation, evoked by insults such as infection, trauma, surgery, and ischemia-reperfusion injury, is another serious complication associated with high morbidity (2) . The question why some patients are more susceptible to developing these complications than others is intriguing and raises the possibility of genetic predisposition. Certain genetic variants of innate immunity genes would thus orchestrate different responses to apparently similar insults (3, 4) .
The innate immune system represents the immediate response toward injury, before amplification of the adaptive immune system. Part of innate immunity is started when membrane-bound, soluble, or intracellular receptor proteins recognize highly conserved pathogen-or danger-associated molecular patterns (5) . Mannose-binding lectin (MBL), H-ficolin, and M-ficolin are examples of soluble pattern recognition molecules, able to bind certain patterns of chemical structures on microorganisms or altered cells in the body. These molecules are found in complexes with MBL-associated serine proteases (MASP-1, MASP-2, or MASP-3) and with MBL-associated proteins (e.g., MAp-44). Binding of MBL/MASP or ficolin/MASP complexes to a fitting pattern activates and regulates inflammation through initiation of the lectin pathway of the complement system (6, 7) .
Both insufficient and excessive activation of the lectin pathway may be detrimental. Whereas deficiency of some of these components may be clinically irrelevant in healthy individuals due to redundancy of the immune system, an increased susceptibility to secondary infections or complications was shown, e.g., deficiency in MBL or ficolins, in children with cancer or neonates with necrotizing enterocolitis (NEC) (8) (9) (10) . In contrast, increased levels of innate immunity proteins, possibly in part explained by polymorphisms in the corresponding genes, may contribute to exaggerated inflammatory responses as observed in acute respiratory distress syndrome (11, 12) .
Data on the lectin pathway of complement activation in critically ill children are scarce. We measured serum levels of different proteins of this pathway on admission in a large cohort of critically ill children (n = 700), compared with those in healthy children (n = 130), and assessed their association with baseline characteristics and clinical outcomes (new ICU infections, duration of ICU stay, and mortality). We hypothesized that baseline deficiencies in these proteins, i.e., on admission to the ICU, may be associated with more infectious complications and poor outcome. In addition, we investigated the impact of functional polymorphisms on circulating protein levels and outcomes of critical illness.
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RESULTS

Lectin Pathway Proteins in Serum From Critically Ill Children and Healthy Controls
In healthy children, MASP-1 and MASP-3 varied with age, with the highest MASP-1 and lowest MASP-3 levels in children younger than 1 y of age (Figure 1a) . Due to the inherent difficulty of recruiting healthy children in this youngest group, there was an imbalance between the age of the critically ill (1.3 (0.3-5.0) y) and healthy children (4.6 (2.2-6.8) y; P < 0.0001). To avoid bias due to this age difference, we selected two matched cohorts of critically ill children and controls through propensity score matching ( Table 1 ). In the matched population, on-admission levels of MASP-1, MASP-2, MASP-3, and MAp-44 in critically ill patients were significantly lower than the levels in healthy controls (Table 1) . Conversely, M-ficolin levels were higher in critically ill patients. MBL and H-ficolin levels were comparable in both groups.
Lectin Pathway Proteins on ICU Admission in Relation to Baseline Characteristics
In critically ill children, on-admission levels of the proteins increased with age, except for an inverse relation for MASP-1 and MAp-44 ( Figure 1b and Critically ill children. Protein levels were compared among children aged less than 1 y (white boxes, n = 9 and n = 303, respectively, for healthy and critically ill children), between 1 and 4 y (hatched white boxes, n = 44 and n = 166, respectively), between 4 and 8 y (grey boxes, n = 52 and n = 89, respectively), and older than 8 y (hatched grey boxes, n = 25 and n = 113, respectively). Data are expressed as box plots, where the central lines indicate the medians, the boxes indicate the interquartile ranges, and the whiskers represent the 10th and 90th percentiles. *0.05 < P < 0.1; **P < 0.001; † P < 0.0001 in Kruskal-Wallis test. MASP, MBL-associated serine protease; MBL, mannose-binding lectin. In a univariate analysis, patients who acquired an infection at any time in ICU had lower on-admission MASP-3 levels than those who did not acquire an infection (P < 0.0001; Figure 2a ). The other proteins were not associated with infection (data not shown). After correcting for baseline characteristics, risk factors, and the other lectin pathway proteins in multivariate logistic regression analysis, low MASP-3 levels remained independently associated with acquisition of infection ( Table 3) . Indeed, the corresponding odds ratio and 95% confidence interval of 0.809 (0.675-0.959) per µg/ ml MASP-3 added (P = 0.02) illustrate a lower risk of infection for a higher on-admission MASP-3 level. Performance of on-admission MASP-3 levels in the prediction of infection (area under the curve of 0.64) was somewhat better than that of C-reactive protein (CRP; area under the curve of 0.58; Figure 3 ). MASP-3 and CRP levels did not correlate (data not shown).
In a univariate analysis, lower on-admission MASP-3 levels were observed in patients needing a prolonged ICU stay (at least 3 d) than in patients with a shorter ICU stay (P < 0.0001; Figure 2b) . A similar relation was found between lower levels of on-admission MASP-2 (0.16 (0.11-0.24) vs. 0.18 (0.13-0.27) µg/ml; P = 0.002) or H-ficolin (20.73 (16.60-25 .75) vs. 22 .08 (18.20-28.77 ) µg/ml; P = 0.002) and prolonged ICU stay. There was no association between the levels of the other proteins and ICU stay. In multivariate Cox proportional hazard analysis, correcting for baseline risk factors and the other lectin pathway proteins, a low on-admission MASP-3 (but not MASP-2 or H-ficolin) level remained an independent risk factor for prolonged time to ICU discharge ( Table 4 ). The hazard ratio and 95% confidence interval were 1.088 and 1.020-1.157, respectively (P = 0.01), indicating a higher likelihood of earlier alive ICU discharge at any time with a higher on-admission MASP-3 level. The predictive value of MASP-3 for the likelihood of early alive discharge was maintained when acquisition of a new infection was added to the model (hazard ratio: 1.080 (1.009-1.152); P = 0.03). The corresponding hazard ratio for infection was 0.238 (0.191-0.296; P < 0.0001). There was no association between the levels of any of the proteins measured on ICU admission and ICU mortality (data not shown).
Association of Genetic Polymorphisms in the MASP1 Gene With Protein Levels and Outcomes of Critical Illness
Because only MASP-3 levels were related to outcomes, we studied only single-nucleotide polymorphisms (SNPs) in (13) calculated with only the admission value of blood glucose, which is unaffected by the study intervention. Similar associations were observed with the Risk Adjustment in Congenital Heart Surgery (RACHS) score for patients undergoing cardiac surgery for congenital heart disease, with a higher score indicating a higher risk of death (14). For all SNPs, allele frequencies showed a similar distribution in patients and controls ( Table 5 ) and were consistent with Hardy-Weinberg equilibrium. However, for five SNPs, more than 5% of the samples could not be attributed to a genotype. Of the remaining SNPs, 18 were monomorphic or near monomorphic, with less than 1% attributed to a genotype different from the ancestral allele homozygosity. These 23 SNPs were not further considered. In univariate analysis, only rs710469 (C>T, intron SNP) and rs850312 (G>A, synonymous SNP in coding region) were associated with MASP-3 levels. More specifically, rs710469 variant allele (T) homozygosity and presence of a variant allele (A) in rs850312 were associated with higher MASP-3 levels (Figure 4a,b) . Taking into account the relationship between higher MASP-3 and better outcome, we considered the rs710469 TT and rs850312 AA or AG genotypes as "protective. " Combining the two SNPs as one endpoint, patients having maximally one protective genotype had lower MASP-3 levels than patients having both protective genotypes ( Figure  4c) . Similarly, patients without any protective SNP had lower MASP-3 levels than patients having at least one protective SNP (Figure 4d) . In multiple linear regression analysis using age, PRISM score, and genotype, having an ancestral allele in rs710469 (CC or CT) or homozygosity in the ancestral allele for rs850312 (GG)-i.e., having maximally one protective SNPdetermined low MASP-3 levels, independent of-and without any significant interaction with-younger age and higher severity of illness ( Table 6) . Similar results were obtained for patients having no protective SNP (data not shown). rs710469 and rs850312 were not associated with the acquisition of infection or time in ICU in univariate or multivariate analysis with or without the MASP protein levels present in the model.
DISCUSSION
Critically ill children with varying underlying pathology show altered serum profiles of several lectin pathway proteins, with low MASP and high M-ficolin levels, on ICU admission compared with healthy children. Low MASP-3 levels, in particular, were robustly associated with a higher risk of acquiring a new infection in the ICU and prolonged need for intensive care. Age, severity of illness, and genetic variation in the MASP1 gene independently explained the variation in MASP-3 levels 
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Articles on ICU admission. However, genetic variation did not by itself contribute to the risk of infection and prolonged critical illness.
Critically ill children showed lower levels of MASP-1, MASP-2, MASP-3, and MAp-44 and higher M-ficolin levels on ICU admission than age-matched healthy children, whereas levels of MBL and H-ficolin were comparable. Thus, critical illness has an acute effect on most of these proteins. Matching for age appeared crucial because of the important changes with age reported for most of these proteins (10, (15) (16) (17) (18) and largely confirmed in our cohorts of healthy and critically ill children.
We observed higher levels of MASP-2 and H-ficolin in critically ill patients with a history of malignancy than in those without. Elevated levels of MASP-2 and MBL, but not of M-ficolin, have been reported for children with cancer (19, 20) . Low levels of MASP-2 and H-ficolin have been associated with fever, neutropenia, bacteremia, prolonged hospitalization, and intravenous antimicrobial therapy (9, 21) . Data on the lectin pathway in pediatric critical illness are scarce and available only for small cohorts of neonates. Low MBL and high M-ficolin levels in umbilical cord blood have been associated Articles Ingels et al.
with Gram-negative and early-onset sepsis, and low H-ficolin levels have been associated with susceptibility to Gram-positive and late-onset sepsis (22, 23) . Low MBL levels in blood from neonates were related to an increased risk of neonatal sepsis and pneumonia (24, 25) . Cord blood MASP-2 levels tended to be higher for babies with infections (26) and were higher for neonates who developed NEC (17) . Risk of death and need for mechanical ventilation for neonates with NEC were higher when M-ficolin levels were low (10) . Major surgery was shown to lead to an initial decrease in MASP-1, MASP-3, and MAp-44 levels, followed by gradual recovery (15, 16) . In our cohort of critically ill children, low on-admission MASP-3 levels were robustly associated with an increased risk of acquiring a new infection, even after correcting for baseline characteristics, risk factors, and the other lectin pathway proteins. The likelihood for an earlier alive discharge from ICU was also much lower for patients with low on-admission levels of MASP-3 in multivariate analysis. The latter association was only partially attributable to the higher infection rate in these patients because the effect of MASP-3 was somewhat attenuated but remained significant when acquisition of a new infection was added to the statistical model. The biological activity of MASP-3 remains incompletely understood. Recombinant MASP-3 has some activity on insulin-like growth factor-binding protein-5 and some synthetic substrates (27) . A critical role of MASP-3 in insulin-like growth factor-binding protein-5 availability during craniofacial, muscle, and neural crest development was suggested based on specific mutations (28) (29) (30) . In mice, MASP-1 and MASP-3 play a role in the alternative pathway of complement activation and thus might act as a backup system when the lectin pathway is deficient (31) . However, the alternative complement activation pathway functioned normally in a patient deficient in MASP-1 and MASP-3 due to a nonsense mutation in the common part of the MASP1 gene (32). Our findings suggest that MASP-3 plays an important role in the host defense against infections in the ICU and may also be of much broader importance as low MASP-3 was associated with prolonged need for intensive care irrespective of infection.
We observed an inverse correlation between on-admission MASP-3 levels and severity of illness, suggesting a more severe acute depression of MASP-3 for sicker patients. Interest in the functional consequences of genetic variation in determining susceptibility and response to disease is increasing, also in critical illness (3, 4, 33, 34) . Our study of several SNPs spread throughout the MASP1 gene encoding MASP-3 (7,35) identified two SNPs for which the variant allele was associated with higher on-admission MASP-3 levels. These "protective" genotypes were equally distributed among patients and controls; thus, not having a protective genotype did not predispose to critical illness. Carrying one protective SNP variant appeared sufficient for having higher MASP-3 levels because having both the protective SNPs was not more protective than having only one. The variation in MASP-3 levels was only partially explained by this genetic variation because age and illness severity were additional independent determinants of these protein levels, without interaction with genetic variation. The actual protein level of MASP-3 appeared more important for outcome than genetic variation in the MASP1 gene. Indeed, whereas low on-admission protein levels were clearly associated with risk of infection and prolonged ICU stay, carrying a protective 
Articles SNP variant obviously was not sufficient to compensate for the impact of the acute insult of critical illness that reduces MASP-3 levels and was not associated with risk of infection or ICU stay.
The major strength of our unique study is that it evaluated a wide array of lectin pathway proteins in large cohorts of healthy children and critically ill children with varying underlying pathology and of all ages, in addition to combining this with genetic analyses. However, a first limitation of our study is that although we found robust associations between onadmission MASP-3 levels and clinical outcomes, our study does not provide hard evidence for causal involvement. This would require artificial interference with MASP-3 levels in a randomized study. A second limitation relates to the number of SNPs analyzed. The selected SNPs covered exons, introns, and the 5′-and 3′-untranslated regions of the MASP1 gene. Nevertheless, we did not study all genetic variations in the MASP1 gene, and hence, we cannot exclude the importance of any other SNPs for the outcome of critically ill children. Moreover, several SNPs did not show any, or showed insufficient, variation in our cohorts, hampering the study of any relation with outcome.
In conclusion, in a large unselected heterogeneous cohort of critically ill children, we observed remarkable disturbances in several proteins of the lectin pathway of complement activation on ICU admission. We identified a low circulating MASP-3 protein level as an independent predictor of subsequent acquisition of infection and prolonged dependency on intensive care. The impact of critical illness appeared to overwhelm any impact of protective SNPs on MASP-3 protein levels. These intriguing results open the way for further investigation of the role of MASP-3 in general and in critical illness in particular. Obviously, additional pathophysiological research will be needed to further elucidate the role of the lectin pathway of complement activation during critical illness. To convert glucose to mmol/l, multiply by 0.05551.
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METHODS
Subjects
This is a preplanned analysis of all patients (n = 700) included in a randomized controlled study on tight glycemic control in the pediatric ICU (1). Patients had been allocated to conventional insulin therapy (n = 351, insulin started only when blood glucose exceeded 215 mg/dl, and the dose was tapered down and stopped when glycemia decreased to levels less than 180 mg/dl) or intensive insulin therapy (n = 349, insulin infused to achieve age-adjusted normal fasting glucose levels). Patient characteristics were comparable for both randomization groups ( Table 7) . Intensive insulin therapy reduced nosocomial infections, ICU stay, and ICU mortality (1) . As controls, we included 130 healthy children ( Table 7) scheduled for minor ambulatory surgery, allowing preoperative blood withdrawal after catheterization required for induction and/or maintenance of anesthesia. The study was approved by the KU Leuven Institutional Review Board (ML2586 and amendment) and was registered with ClinicalTrials.gov (NCT00214916). The study was performed in accordance with the 1964 Declaration of Helsinki and its amendments. Written informed consent was obtained from the parents or legal guardians of patients and controls.
Biochemical and Genetic Analyses
CRP was determined by routine clinical chemistry. Whole arterial blood glucose was measured at 1-to 4-h intervals using the ABL700 blood gas analyzer (Radiometer Medical A/S, Copenhagen, Denmark). On ICU admission, serum and blood cell samples for DNA extraction were collected and stored at −80 °C until analysis. For 29 and 90 patients, no baseline serum or blood cell sample was available, respectively. Probe sequences are given for custom-made assays.
